249 related articles for article (PubMed ID: 30778902)
1. A high-risk luminal A dominant breast cancer subtype with increased mobility.
Guo L; Chen G; Zhang W; Zhou L; Xiao T; Di X; Wang Y; Feng L; Zhang K
Breast Cancer Res Treat; 2019 Jun; 175(2):459-472. PubMed ID: 30778902
[TBL] [Abstract][Full Text] [Related]
2. Increased RNA Expression of von Willebrand Factor Gene Is Associated With Infiltrating Lobular Breast Cancer and Normal PAM50 Subtype.
Lehrer S; Green S; Dembitzer FR; Rheinstein PH; Rosenzweig KE
Cancer Genomics Proteomics; 2019; 16(3):147-153. PubMed ID: 31018945
[TBL] [Abstract][Full Text] [Related]
3. Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism.
Du T; Zhu L; Levine KM; Tasdemir N; Lee AV; Vignali DAA; Houten BV; Tseng GC; Oesterreich S
Sci Rep; 2018 May; 8(1):7205. PubMed ID: 29739984
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
5. Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration.
Pignatelli J; Goswami S; Jones JG; Rohan TE; Pieri E; Chen X; Adler E; Cox D; Maleki S; Bresnick A; Gertler FB; Condeelis JS; Oktay MH
Sci Signal; 2014 Nov; 7(353):ra112. PubMed ID: 25429076
[TBL] [Abstract][Full Text] [Related]
6. Epigenomic and Transcriptomic Characterization of Secondary Breast Cancers.
Graff-Baker AN; Orozco JIJ; Marzese DM; Salomon MP; Hoon DSB; Goldfarb M
Ann Surg Oncol; 2018 Oct; 25(10):3082-3087. PubMed ID: 29956094
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis.
Gándara-Cortes M; Vázquez-Boquete Á; Fernández-Rodríguez B; Viaño P; Ínsua D; Seoane-Seoane A; Gude F; Gallego R; Fraga M; Antúnez JR; Curiel T; Pérez-López E; García-Caballero T
Virchows Arch; 2018 Feb; 472(2):195-203. PubMed ID: 28825136
[TBL] [Abstract][Full Text] [Related]
8. Heat Shock Protein 90 Family Isoforms as Prognostic Biomarkers and Their Correlations with Immune Infiltration in Breast Cancer.
Lin T; Qiu Y; Peng W; Peng L
Biomed Res Int; 2020; 2020():2148253. PubMed ID: 33145341
[TBL] [Abstract][Full Text] [Related]
9. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.
Adachi Y; Ishiguro J; Kotani H; Hisada T; Ichikawa M; Gondo N; Yoshimura A; Kondo N; Hattori M; Sawaki M; Fujita T; Kikumori T; Yatabe Y; Kodera Y; Iwata H
BMC Cancer; 2016 Mar; 16():248. PubMed ID: 27015895
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
12. Refinement of breast cancer classification by molecular characterization of histological special types.
Weigelt B; Horlings HM; Kreike B; Hayes MM; Hauptmann M; Wessels LF; de Jong D; Van de Vijver MJ; Van't Veer LJ; Peterse JL
J Pathol; 2008 Oct; 216(2):141-50. PubMed ID: 18720457
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer metastasis to gynaecological organs: a clinico-pathological and molecular profiling study.
Kutasovic JR; McCart Reed AE; Males R; Sim S; Saunus JM; Dalley A; McEvoy CR; Dedina L; Miller G; Peyton S; Reid L; Lal S; Niland C; Ferguson K; Fellowes AP; Al-Ejeh F; Lakhani SR; Cummings MC; Simpson PT
J Pathol Clin Res; 2019 Jan; 5(1):25-39. PubMed ID: 30246500
[TBL] [Abstract][Full Text] [Related]
14. Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer.
Khokher S; Qureshi MU; Mahmood S; Nagi AH
Asian Pac J Cancer Prev; 2013; 14(5):3223-8. PubMed ID: 23803108
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer pathology: the impact of molecular taxonomy on morphological taxonomy.
Masuda S
Pathol Int; 2012 May; 62(5):295-302. PubMed ID: 22524656
[TBL] [Abstract][Full Text] [Related]
16. ESPL1 is a candidate oncogene of luminal B breast cancers.
Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.
Viale G; de Snoo FA; Slaets L; Bogaerts J; van 't Veer L; Rutgers EJ; Piccart-Gebhart MJ; Stork-Sloots L; Glas A; Russo L; Dell'Orto P; Tryfonidis K; Litière S; Cardoso F;
Breast Cancer Res Treat; 2018 Jan; 167(1):123-131. PubMed ID: 28929359
[TBL] [Abstract][Full Text] [Related]
18. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
19. Identification of Novel Breast Cancer Risk Loci.
Chan CHT; Munusamy P; Loke SY; Koh GL; Wong ESY; Law HY; Yoon CS; Tan MH; Yap YS; Ang P; Lee ASG
Cancer Res; 2017 Oct; 77(19):5428-5437. PubMed ID: 28775167
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotype-associated gene signature in ductal breast tumors varies by receptor subtype, but the expression of individual signature genes remains consistent.
Behring M; Ye Y; Elkholy A; Bajpai P; Agarwal S; Kim HG; Ojesina AI; Wiener HW; Manne U; Shrestha S; Vazquez AI
Cancer Med; 2021 Aug; 10(16):5712-5720. PubMed ID: 34189853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
